Clinical trials: Asthma, Allergic
Asthma, House Dust Mite Allergy
Dose Ranging Study of SLIT Tablets of House Dust Mite Allergen Extracts (HDM) in Adults With HDM-associated Allergic Asthma
The purpose of this study is to investigate the efficacy and safety of different doses of sublingual tablets of house dust mite allergen extracts as compared to placebo in adults with house dust mite-associated allergic asthma.
- Trial name
- NCT01930461
- Testing
- SLIT tablets of HDM allergen extracts, 3 different doses (A), SLIT tablets of HDM allergen extracts, 3 different doses (B), SLIT tablets of HDM allergen extracts, 3 different doses (C)
- Where
- 5 sites in France, Germany and 1 more
- Volunteers
- 386 people
- Sponsor
- Stallergenes Greer
Chronic Refractory Cough (CRC) With Non-atopic Asthma, CRC With Atopic Asthma
A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough
This Phase IIa, multicenter, randomized, double-blind, placebo-controlled, crossover study will evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamic (PD) effects of GDC-6599 compared with placebo in patients with…
- Conditions
- Chronic Refractory Cough (CRC) With Non-atopic Asthma, CRC With Atopic Asthma, Unexplained Chronic Cough, CRC With Chronic Obstructive Pulmonary Disease
- Trial name
- NCT05660850
- Testing
- GDC-6599, Mannitol
- Where
- 18 sites in United States, Australia and 2 more
- Volunteers
- 49 people
- Sponsor
- Genentech, Inc.
Eosinophilic Esophagitis
Expanded Access Protocol for Patients With Eosinophilic Esophagitis
This expanded access program is an open-label, single-arm design where consenting patients may participate up until APT-1011 is commercially available in the relevant regions or the protocol is terminated by the Sponsor.
- Trial name
- NCT05095116
- Testing
- APT-1011 3 mg HS
- Where
- 35 sites in United States
- Sponsor
- Ellodi Pharmaceuticals, LP
Asthma, Allergic
Effects of Puressentiel Purifying Spray on Asthma Control in Patients With Mild to Moderate Allergy-induced Asthma.
The main objective of this study is to evaluate, in real life, the efficacy of prolonged use (6 months) of Puressentiel Air Purifying Spray with 41 essential oils on the control of allergy-induced asthma in the homes of patients…
- Trial name
- PSIndAC (NCT05352126)
- Testing
- Biocide
- Volunteers
- 80 people
- Sponsor
- Puressentiel
Asthma
CYT003 in Patients With Mild to Moderate Allergic Asthma Not Sufficiently Controlled on Inhaled Glucocorticosteroids
A phase IIb study in patients to evaluate CYT003- QbG10 versus placebo, in patients with mild to moderate allergic asthma not sufficiently controlled on inhaled steroid.
- Trial name
- NCT02087644
- Testing
- CYT003
- Where
- United States
- Sponsor
- Cytos Biotechnology AG
Moderate-to-severe Allergic Asthma
A Study to Assess the Impact of Omalizumab on Exercise Capacity, Physical Activity, and Sleep Quality in Participants With Moderate to Severe Allergic Asthma
This study will assess the effect of omalizumab on exercise capacity, physical activity, and sleep quality after 24 weeks of treatment in participants with moderate to severe allergic asthma.
- Trial name
- EDURO (NCT04195958)
- Testing
- Omalizumab
- Where
- 12 sites in United States
- Volunteers
- 3 people
- Sponsor
- Genentech, Inc.
Allergic Rhinitis, Asthma
Comparative Real World Effectiveness of SQ Sublingual Immunotherapy (SLIT)-Tablets vs. Controls in Allergic Rhinitis and Asthma
To assess the impact of SQ SLIT-tablets (SQ Grass SLIT-tablet and SQ HDM SLIT-tablet) in Danish and Swedish allergic rhinitis (AR) patients, with or without asthma, between 2007-2020.
- Conditions
- Allergic Rhinitis, Asthma, Allergy
- Trial name
- RELY (NCT05476484)
- Testing
- SQ SLIT-tablet
- Where
- Denmark
- Volunteers
- 46,196 people
- Sponsor
- ALK-Abelló A/S
Asthma, House Dust Mite Allergy
Safety Study of Sublingual Immunotherapy Tablets of House Dust Mite Allergen Extracts
The purpose of this study is to investigate the safety of different doses of sublingual tablets of house dust mite allergen extracts in adults with house dust mite-associated allergic asthma.
- Trial name
- NCT01608243
- Testing
- SLIT tablets of house dust mite allergen extracts
- Where
- France
- Volunteers
- 94 people
- Sponsor
- Stallergenes Greer
Allergy
Efficacy of SLITone in House Dust Mite Allergic Patients
This trial has been designed to evaluate the efficacy of specific immunotherapy with SLITone Dermatophagoides mix compared with placebo in subjects with house dust mite allergic asthma, based on asthma medication use during a…
- Trial name
- NCT00633919
- Testing
- SLITone(TM) Dermatophagoides mix, Salbutamol inhaler, Budesonide/formoterol inhaler
- Where
- Spain
- Volunteers
- 124 people
- Sponsor
- ALK-Abelló A/S
Allergic Rhinoconjunctivitis
Subcutaneous Immunotherapy in Patients Sensitized to Phleum Pratense
Based on EMA (European Medicines Agency) new guidelines on the clinical development of products for immunotherapy for the treatment of allergic disease the aim of this study was to assess safety and tolerability of three…
- Trial name
- NCT01489033
- Testing
- Subcutaneous immunotherapy with Phleum pratense pollen extract
- Where
- Spain
- Volunteers
- 42 people
- Sponsor
- Roxall Medicina España S.A
Perennial Allergic Rhinitis, Asthma
Observational Study to Evaluate Therapeutic Effectiveness and Safety of Monterizine Cap.
Investigator examines the past prescription patterns and the reasons for the change of prescription to Monterizine capsules for Perennial Allergic Rhinitis patients with Asthma who will be taking Monterizine capsules to treat…
- Trial name
- NCT04654702
- Where
- South Korea
- Volunteers
- 2,671 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Allergic Rhinoconjunctivitis
Phase II Trial With Subcutaneous Immunotherapy in Patients Sensitized to Phleum Pratense
Based on EMA (European Medicines Agency) new guidelines on the clinical development of products for immunotherapy for the treatment of allergic diseases the aim of this study is to establish a dose-response relationship for…
- Trial name
- NCT01567306
- Testing
- Allergovac Depot
- Where
- 10 sites in Portugal, Spain
- Volunteers
- 151 people
- Sponsor
- Roxall Medicina España S.A
Allergic Bronchopulmonary Aspergillosis
Study in Adult Asthmatic Patients With Allergic Bronchopulmonary Aspergillosis
A Randomized, Double-Blind, Multicenter, Placebo-Controlled, Phase 2 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Itraconazole Administered as a Dry Powder for Inhalation (PUR1900) in Adult Asthmatic…
- Trial name
- NCT03960606
- Testing
- PUR1900
- Where
- 20 sites in United States, Australia and 3 more
- Volunteers
- 7 people
- Sponsor
- Pulmatrix Inc.
Asthma
Omalizumab in Adult and Adolescent Patients With Severe Persistent Allergic Asthma
Omalizumab will be given as add-on treatment to optimized asthma therapy in patients with severe persistent asthma, who demonstrate inadequate asthma symptom control.
- Trial name
- NCT00264849
- Testing
- Omalizumab, Optimized asthma therapy
- Where
- 17 sites in Belgium, Canada and 15 more
- Volunteers
- 406 people
- Sponsor
- Novartis
Asthma, Allergy
Glasgow Asthma and Allergy Study
In the past, doctors separated people with asthma into two groups, those with "allergic asthma" (about 2/3rds of people) and those with "non-allergic asthma".
- Trial name
- GLAAS (NCT01618318)
- Where
- United Kingdom
- Volunteers
- 105 people
- Sponsor
- National Services for Health Improvement Ltd
Mite Allergy, Dermatophagoides Farinae Allergy
Retrospective Study Evaluating the Effectiveness and Safety of Immunotherapy With Clustoid Max Forte
House dust mites are the main source of allergies in indoor environments. They are predominant in coastal areas, with the Canary Islands being the autonomous community with the highest percentage of patients with…
- Conditions
- Mite Allergy, Dermatophagoides Farinae Allergy, Dermatophagoides Pteronyssinus Allergy, Rhinitis, Allergic
- Trial name
- NCT07427576
- Testing
- Clustoid® Max Forte
- Where
- 2 sites in Spain
- Volunteers
- 140 people
- Sponsor
- Inmunotek S.L.
Allergic Rhinoconjunctivitis
Study for Evaluating Life Quality in Patients With Rhinoconjunctivitis
The purpose of ths study is to evaluate changes in life quality of patients affected by rhinoconjuntivitis with or without asthma after immunotherapy treatment.
- Trial name
- ÍCARA (NCT02488447)
- Where
- 14 sites in Spain
- Volunteers
- 215 people
- Sponsor
- Roxall Medicina España S.A
Asthma
Efficacy and Safety Trial of the ALK HDM Tablet in House Dust Mite Allergic Subjects
The purpose of the trial is to determine if treatment of asthma patients allergic to house dust mites with the ALK HDM tablet can reduce the need of inhaled corticosteroids (ICS).
- Trial name
- NCT00389363
- Testing
- ALK HDM tablet
- Where
- Denmark
- Volunteers
- 800 people
- Sponsor
- ALK-Abelló A/S
Asthma, Allergy
ATEM (Alvesco Non-interventional Study)
The aim of the study is to evaluate the efficacy of Alvesco in patients with persistent asthma including or excluding allergic components over 3 months, especially in the spring season.
- Trial name
- ATEM (NCT01147224)
- Testing
- Alvesco
- Where
- 79 sites in Austria
- Volunteers
- 400 people
- Sponsor
- AstraZeneca
Healthy Volunteers
Study of Pharmacokinetics, Pharmacodynamics and Safety Assessment of GNR-044 (JSC GENERIUM, Russia) and Xolair®
An open-label, randomized, in parallel groups comparative study of pharmacokinetics, pharmacodynamics, immunogenicity and safety of GNR-044 (JSC "GENERIUM", Russian Federation) and Xolair® ("Novartis Pharma AG", Switzerland)…
- Trial name
- NAP (NCT04601389)
- Testing
- Omalizumab (JSC "GENERIUM", the Russian Federation), Xolair® (Novartis Pharma AG, Switzerland)
- Where
- 2 sites in Russia
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- AO GENERIUM